IHL : Pre-IND meeting granted with the US FDA regarding IHL-675A for use in preventing ARDS and SAARDS
The purpose of the meeting is to obtain regulatory guidance and agreement on the most efficient clinical development plan to… Read more
Nyrada Receives Firm Commitments to Raise A$11 Million
Highlights: • Firm commitments received to raise A$11 million with strong demand from existing and new investors • Investment commitments… Read more
Nyrada Presentation March 2021- James Bonnar CEO
Incannex initiates sixth research program following more positive in vivo results; IHL-675A for rheumatoid arthritis
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce that it… Read more
S & P Dow Jones Indices Announce March 2021 Rebalance of the Indices
Incannex Partners with the Monash Trauma Group to assess IHL-216A in a model of sports concussion
Clinical stage cannabinoid development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce that it… Read more